---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-299482"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2022-12-06T23:59:59+00:00"
generated_at: "2026-06-21T08:56:50.264100+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# ARS Pharmaceuticals updates corporate presentation; no material new data disclosed

## Summary
- Company released an updated slide deck for investor meetings on December 6, 2022.
- Presentation highlights needle-free epinephrine solution for Type I allergic reactions.
- No new clinical, regulatory, or financial milestones were announced in the filing.

## SEC filing metadata
- accession: 0001193125-22-299482
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2022-12-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312522299482/0001193125-22-299482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312522299482/d363617d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-299482
- JSON: https://secwatch.observer/filing/0001193125-22-299482.json
- Plain text: https://secwatch.observer/filing/0001193125-22-299482.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.